Last week, the FDA approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. This approval will help offer additional aid for the many individuals throughout the world who live ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

POTIGA (ezogabine) 50mg, 200mg, 300mg, 400mg tablets by GlaxoSmithKline The FDA has approved Potiga (ezogabine tablets; Valeant and GlaxoSmithKline) as adjunct treatment for partial-onset seizures in ...

SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced results of a Phase III trial demonstrating that its antiepileptic drug (AED) in development Keppra XR(TM) (levetiracetam) extended-release tablets ...

BRUSSELS, BELGIUM--(MARKET WIRE)--Oct 29, 2008 -- Brussels, BELGIUM, October 29, 2008 at 7:00 CET- press release, regulated information - UCB announced today that the U.S. Food and Drug Administration ...

Paladin Labs Inc., a subsidiary of Endo International plc, announced that Xcopri (cenobamate tablets) is now available in Canada. Xcopri is indicated as adjunctive therapy in the management of partial ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for the antiepileptic drug lacosamide (Vimpat, UCB) as monotherapy in treating partial-onset seizures in ...

Moving forward The CDC reports that one in 100 U.S. adults has active epilepsy, and studies suggest that one third of these are not receiving adequate treatment or care. 30 Although this recent report ...